Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New innovative approaches harnessing gene therapy, drug delivery and artificial intelligence are proving successful to help treat diseases of the eye. Here we explore emerging technologies and therapies from companies working in the field.
Isarna Therapeutics’ antisense therapy targeting transforming growth factor beta 2, ISTH0036, is about to enter phase 2 clinical development for two retinal diseases: wet age-related macular degeneration and diabetic macular edema.
Catalyst Biosciences has built a protease medicines platform for engineering protease therapeutics designed to correct disease-causing imbalances in biological cascades. The company currently focuses on disorders in the complement or coagulation systems, but has the potential to address additional diseases.
Tarsus is developing its lead candidate TP-03, potentially the first FDA-approved therapy for Demodex blepharitis, and a pipeline of investigational therapies targeting eye care, dermatology, and infectious disease prevention, including Lyme disease and malaria.
InMed Pharmaceuticals, a leader in the development of rare cannabinoid pharmaceutical drug candidates for various diseases, has a portfolio of cannabinol-based clinical and preclinical programs and is focused on advancing its preclinical glaucoma and ocular disease program via partnerships.
NovaGo Therapeutics is developing a first-in-class fully human antibody therapy to treat diabetic retinopathy. With its novel disease-modifying mode of action, it could save the sight of the many patients who respond poorly to current treatments.